Levomilnacipran
CAS: 96847-55-1
Ref. 3D-WDA84755
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen |
Produktinformation
- (1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
- (1R,2S)-Milnacipran
- Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1R,2S)-
- Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1R-cis)-
- Dextromilnacipran
- F 2696
Levomilnacipran is a drug used to treat depression and obsessive-compulsive disorder. Levomilnacipran is a racemic mixture of the R- and S-enantiomers. Levomilnacipran has been shown to be effective in treating bacterial infections in humans. This drug was tested for long-term efficacy as well as concentration-time curves in rats. The clinical properties were also studied in humans. One study showed that levomilnacipran does not have any drug interactions with trifluoroacetic acid, sodium carbonate, or acetylsalicylic acid; however, it may interact with other drugs metabolized by cytochrome P450 enzymes. Levomilnacipran has also been shown to be effective against symptoms of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease.